Presenta tati tion to: o: 1
Our Our Missi ssion To m make g geno enomic t tes esting readily dily availa ilable ble at pric ices everyon yone can affor ord 2
Who o We We Are re WGA is is a an adv dvis isor to to the e lif ife ins nsur urance a e and nd em employee ee ben enef efit broker erage i e ind ndustry. We We are re com ompos osed of f both h sea easoned ned i ins nsur uranc nceexec ecut utives ves an and scie ienti tists ts with h geno enomicback ackgrounds We a e asp spire to be e the e global so source for trust sted ed advi vice rega garding: g: Genomic Science Product Opportunities Global Suppliers Marketplace Intelligence New Developments 3
Our Ex Execu ecutive T e Team eam A. . Greig Woodri dring Chairman of of th the Board rd Dr. P Phili ilip S Smalle lley Chief ief M Medic ical Director Tom Wambe berg rg Chief ief E Executive ive Offic icer er Erin Stalke ker VP, B Busi sine ness ss D Developme ment nt Willia lliam A A. Rope oper Chief ief Finan ancial al Offic icer er Lynnet ette e Bates VP, B Busi sine ness ss D Developme ment nt Mar ark A. A. Winham Chief ef S Scien ientifi ific & Oper erating O Offi fficer Nic ick B Bella llanca Senio ior VP, B Busin ines ess D Deve velopment Jame mes M s M. Benso son Lead D d Direc ector or 4
Wamb mberg Genomi omic Advisor sors i s is a a trust sted source o on G Genom omics 5
Wamberg's 's scien ientific a and m nd medic edical t tea eam c cont ntinually eva valuates provi pr vide ders to assur ure t e the m e most u up-to to-date ate appropriate ate t testing 6
Genomi Ge omic Progr ograms ams Uncover genetic factors that increase disease risk • Guide optimal medication selection and dosage for • improved outcomes Highlight risk of inherited diseases • Provide insight into rare diseases • 1 7 0
The R e Real eality of Can Cancer cer 40% chance of developing cancer in our lifetime. Cancer is the cause of over 22% of all deaths A major cause of disability and long term care claims. 28% of cancers are initially misdiagnosed.* 8
The C e Cancer cer G Guar ardian an™ P ™ Program am™ Identif tifie ies most t effectiv ive treatment optio ions Cancer Genomic Profiling Tests are typically NOT Covered by Medicare, Prov ovides th the foll llowin ing valuable ble infor orma mation on: Medicaid and insurance companies. Information that confirms t ms the accu curacy cy o of diagno nosi sis • COST RANGE Information that highlights a s addi ditional o options f for r • potentiall lly m more e effec ective t e treatmen ents, for example: UP TO $7500 Immunotherapy • Targeted therapies (Some Patients need more than one test) • Many people have difficulty Clinical trial participation • affording this testing at the onset of cancer because of high deductibles and co-pays. 9
Gen enomic M Med edici cine in the R e Real eal W World: : ‘Ho Hope’ a and ‘ d ‘Hy Hype pe’ Success Stori ries It’s the story of Nicholas Volker, a then 4-year-old boy who had undergone more than 100 surgeries in his lifetime, including a colon removal, and basically lived in a hospital as doctors tried to identify the rare disorders he was dying from. It was 2009, and his doctors, having tried everything else, turned to something virtually untried, DNA sequencing, to see if they could identify gene mutations leading to his disorders. “They found he had two changes in his DNA, and they figured he would respond well to a bone marrow transplant. Now he lives a normal life,” Kucherlapati said. Forbes Magazine called him “The First Child Saved by DNA Sequencing. -Chris Orchard, Harvard T.H. Chan School of Public Health 10
Cancer r Genomic ic P Profilin ing C g Clinic ical l Study dy STUDY 1 1 Clinical study of overall survival data for 805 patients with (NSCL) non small-cell lung cancer: Surv urvival Ra Rates s For the 131 patients who received a targeted • 31.8 31.8 mont nths therapy based off patient’s genetic profile at some time during their treatment, the median versu sus s overall survival was 31.8 months. 12.7 12.7 mont nths or r In contrast, of the 482 patients who received • 5.1 5.1 mont nths cytotoxic chemotherapy (most common type of cancer treatment), the median overall survival was 12.7 months and was 5.1 months for the * In some cases complete remission 192 patients who received only supportive care. * AmericanSocietyofClinicalOncology,Volume13/Issue2/February2017inJournalofOncologyPractice *- Gutierrez, Martin E., Kelly Choi, Richard B. Lanman, Edward J. Licitra, Stanley M. Skrypczak, Ruth PeBenito, Tommy Wu, Srikesh Arunajadai, Sukhi Kaur, Harry Harper, Andrew L. Pecora, Eric V. Schultz, and Stuart L. Goldberg. “Genomic Profiling of Advanced 11 Non–SmallCellLungCancerinCommunitySettings:GapsandOpportunities.”GenomicProfilingofAdvancedNon– SmallCellLungCancerinCommunitySettings:GapsandOpportunities- ScienceDirect. ElsevierInc.,13Apr.2017.Web.21July 2017. http://www.sciencedirect.com/science/article/pii/S1525730417301092
Ex Excl clusive e LifeMa Mark rk Cancer er G Guar ardian an™ P ™ Program am Produce cers can can offer C Can ance cer G Guar ardian™ t to A All NEW p poli licyholde lders First year progr gram charge rges waived ved for poli licyholde lder & & child ldren On t the f first poli licy a anniv iversary, p partic ticipa ipants ts may contin tinue t the p program v via direct b t billi illing f from WGA Program c charges rges r range f e from $ $8-15 p 15 per partic ticipa ipant p t per m month th – age e banded ed rates es 12
Cancer cer G Guar ardian an™ P ™ Program am Advan antag ages es Fo For T The P Produce cer Exclusive LifeMark product to be used to drive sales and client retention Enhance client engagement Competitive advantage at point of sale at no cost to producer. Will provide your clients with a valuable tool that has the ability to save their lives Producer will be viewed as a partner in supporting their clients long and healthy life 13
The S e Soci ciet etal al V Value Together we strive to continue to find ways to make genomic testing easy and accessible. This will lead to more testing that will create more data and more cures. + + More Mor More Car Mor are More Mor Data ta Paths hs Testin ting = Mor ore Cur ures 14
15
Publ blic Re Rela lations LifeMark and its agency members will be th the f fir irst nati tional f fir irm to offer Cancer Guardian™ to its policyholders. Being the first is NEWS! Industry announcement at the Society of Actuaries conference in March 2018 • Full PR and Marketing campaign provided by Wamberg Genomic + Lead • generation program provided for agents National press coverage campaign • 16
Prog ogram E Execut ution n - Fo Four Eas Easy S Steps Step 1 1. . Agent provides new policyholder printed or digital Cancer Guardian ™ Program Guide at time of life policy placement. Step 2 2. . Agency file of eligible policyholders sent to WGA weekly. Step 3 3. . WGA will reach out to anyone that has not registered their Cancer Guardian™ Program online. Digital • Direct Mail • Phone • 17
Prog ogram E Execut ution n – Fo Four Eas Easy S Steps Step 4 4. . Completion of Program Participation Registration – online or via phone support Ability to add spouse and dependent children • Confirmation e-mail once registration is complete • with electronic version of Program I.D. card. Custom Printed I.D. cards will be made available • when requested at program registration. 18
The e LifeM eMar ark Partn tners rship ip Innovative product offerings to differentiate your team • and drive sales Industry recognition – tools for recruiting • Dedicated implementation, account management, and • client support Full enrollment and communication capabilities • Ongoing Product offerings and engagement • 19
The e LifeM eMar ark Partn tners rship ip Extending Life • Extending Relationships • Making a Difference • 20
Questions & Next Steps Thank you 21
Recommend
More recommend
